Ipsen SA

U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome

13 Jun 2023 13:10:54 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2023

13 Jun 2023 12:00:00 By Nasdaq GlobeNewswire

Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023

12 Jun 2023 01:00:00 By Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

09 Jun 2023 12:00:00 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 22 - 2023

06 Jun 2023 12:00:00 By Nasdaq GlobeNewswire

Ipsen SA initiates a share buy-back program to cover its free employee share-allocation plan

01 Jun 2023 01:00:00 By Nasdaq GlobeNewswire

Ipsen S.A. - Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023

31 May 2023 12:04:12 By Nasdaq GlobeNewswire

Ipsen - Description of the regulatory framework of the share repurchase program to be approved at the Combined Shareholders’ Meeting on 31 May 2023

31 May 2023 01:00:00 By Nasdaq GlobeNewswire

Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.

26 May 2023 08:20:29 By Nasdaq GlobeNewswire

Ipsen to present new Bylvay® (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases

17 May 2023 01:00:00 By Nasdaq GlobeNewswire

Ipsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital - April 2023

10 May 2023 12:00:00 By Nasdaq GlobeNewswire

Ipsen : 2023 CSM - Formalities for making available preparatory documents to the Meeting

10 May 2023 08:00:00 By Nasdaq GlobeNewswire

Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance

27 Apr 2023 01:00:00 By Nasdaq GlobeNewswire

Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs

24 Apr 2023 02:00:00 By Nasdaq GlobeNewswire

Ipsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital

11 Apr 2023 01:00:00 By Nasdaq GlobeNewswire

Ipsen S.A. publishes its 2022 Universal registration document

06 Apr 2023 13:04:01 By Nasdaq GlobeNewswire

Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP

16 Mar 2023 14:02:10 By Nasdaq GlobeNewswire

Ipsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital

10 Mar 2023 12:00:00 By Nasdaq GlobeNewswire

Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio

02 Mar 2023 14:13:06 By Nasdaq GlobeNewswire

Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023

22 Feb 2023 01:00:00 By Nasdaq GlobeNewswire